Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00671073 · ClinicalTrials.gov registry record · Phase 2
Study To Assess Efficacy and Safety of Oglemilast in Patients With Chronic Obstructive Pulmonary Disease (COPD)
A Phase 2 study, sponsored by Forest Laboratories.
- Completed
- Registry status
- Phase 2
- Development phase
- 427
- Enrollment target
NCT00671073 is a Phase 2 study that has completed, run by Forest Laboratories. The registered enrollment target is 427 participants.
The verdict
NCT00671073, a Phase 2 study, has completed, sponsored by Forest Laboratories.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 427 participants
- Enrollment target
Study Summary
This study will assess the safety and efficacy of a range of oglemilast doses. The study will be 14 weeks in duration. All patients meeting the eligibility criteria will be randomized to one of three doses of oglemilast or placebo.
Interventions
- DRUG Placebo
- DRUG Oglemilast
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 427 participants |
| Start Date | 2008-05-05 |
| Est. Completion | 2009-05-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00671073
The ClinicalTrials.gov registry entry for NCT00671073 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 427 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Forest Laboratories, which has 145 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00671073 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00671073 about?
NCT00671073 is a clinical study titled "Study To Assess Efficacy and Safety of Oglemilast in Patients With Chronic Obstructive Pulmonary Disease (COPD)". This study will assess the safety and efficacy of a range of oglemilast doses. The study will be 14 weeks in duration. All patients meeting the eligibility criteria will be randomized to one of three doses of oglemilast or placebo.
What is the current status of trial NCT00671073?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 427 participants. The study started on 2008-05-05. Estimated completion is 2009-05-15.
What interventions are being tested in trial NCT00671073?
The interventions under investigation include: Placebo (DRUG), Oglemilast (DRUG).
Who is sponsoring clinical trial NCT00671073?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.